One of the most common types of brain tumors in adults, glioblastoma multiforme, is one of the most devastating. Even with recent advances in surgery, radiation and chemotherapy, the aggressive and invasive tumors become resistant to treatment, and median survival of patients is only about 15 months.
Epigenetics research has expanded rapidly over the last several years, as evidenced by the exponential increase in published literature in this field. Breakthroughs have been made in the elucidation of basic epigenetic mechanisms such as histone modification, and with these advances have come an understanding of the critical role epigenetic modifications play in the development and progression of cancer.
Following a three-year study using more than 2,800 mice, a University of Missouri researcher was not able to replicate a series of previous studies by another research group investigating the controversial chemical BPA. The MU study is not claiming that BPA is safe, but that the previous series of studies are not reproducible.
The spread of cancer cells may be slowed by targeting the protein km23-1. A motor protein that transports cargo within the cell, km23-1 is also involved in the movement or migration of cells. Migration is necessary for cancer to spread, so understanding this cell movement is important for development of better cancer treatments.
Finding ways to diagnose cancer earlier could greatly improve the chances of survival for many patients. One way to do this is to look for specific proteins secreted by cancer cells, which circulate in the bloodstream. However, the quantity of these biomarkers is so low that detecting them has proven difficult. A new technology may help to make biomarker detection much easier.
A research team has decoded the entire pathway that regulates leakiness of blood vessels — a condition that promotes a wide number of disorders, such as heart disease, cancer growth and spread, inflammation and respiratory distress. They say their findings suggest that several agents already being tested for other conditions might reverse vessel leakiness.
Biologists at UC San Diego have succeeded in genetically engineering algae to produce a complex and expensive human therapeutic drug used to treat cancer. Their achievement opens the door for making these and other “designer” proteins in larger quantities and much more cheaply than can now be made from mammalian cells.
New Technology Allows Scientists to Capture and Preserve Cancer Cells Circulating in the BloodstreamDecember 17, 2012 9:27 am | by RIKEN Advanced Science Institute | News | Comments
Scientists report a new nanoscale Velcro-like device that captures and releases tumor cells that have broken away from primary tumors and are circulating in the bloodstream. This new nanotechnology could be used for cancer diagnosis and give insight into the mechanisms of how cancer spreads throughout the body.
Epigenetics researchers apply sophisticated techniques and rational multidimensional analyses to discover biomarkers for ovarian cancer.
Asuragen, Inc. and Life Technologies Corporation announced that they have completed CE-marking and commercial launch in Europe of the BCR/ABL1 Quant Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML)
The classic view of cancer is that it arises from the progressive accumulation of mutations. The cancer stem cell model, however, theorizes that tumors derive hierarchically from one or more progenitor cells.
febit launched a human cancer biochip for HybSelect, febit's automated technology for sequence capture, enabling targeted Next-Generation Sequencing (NGS).
Rubicon Genomics released its PicoPlex Single Cell Whole Genome Amplification (WGA) kit?a more rapid, accurate and reproducible method for amplifying single genomes than current technologies.
SIRT1 belongs to the class III family of HDACs, which are NAD+ dependent enzymes. SIRT1 modulators have been shown to play a beneficial role in treating diseases such as cancer, diabetes, metabolic disease and inflammation, making them attractive targets for the development of new drugs.
Sigma-Aldrich introduced Precisio Kinases, a new collection of high quality active kinases that is expected to enable scientists to achieve greater insight into protein phosphorylation and cell signaling.
caption Inset, President Nixon signing the National Cancer Act, December 23, 1971. (Source: NCI)
caption Figure 1: Analysis of 2-D gel by Dymension software showing proteins that are up or down-regulated three hours after delta-tocotrienol treatment.
Applied Biosystems, a division of Life Technologies, announced the availability of a new universal genotyping reagent solution that accelerates the generation of high-quality genotyping data for a host of life science applications.
Trevigen introduces a highly sensitive, quantitative and validated assay to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anticancer drug screening.
Millipore has introduced a new line of tissue culture plates pre-coated with a selection of matrices that enhance cell growth and differentiation for stem cell, cancer, cell signaling, and other critical research applications.
A range of assays, kits, flow cytometry systems, and service plans are available in an integrated benchtop flow cytometry portfolio.
caption Fig.1: (a) Assay principle: HTRF Transcreener ADP assay principle: during the enzymatic step, the kinase catalyses the transfer of a phosphate group from ATP to a substrate. For ATPase, ATP is converted into ADP and inorganic phosphate. Then in the detection step, native ADP and d2 labeled ADP compete for the anti-ADP antibody labeled with Eu3+ Cryptate. The signal is inversely proportional to the concentration of ADP in the sample. (b) Standard curve: The standard curve is based on a mixture of ATP and ADP. ATP solutions are serially diluted in ADP solutions in order to mimic the conversion of ATP into ADP (from 0 to 100%): ADP concentration ranges from 0 to 100 µM final.
This 2D gel imager can analyze silver stained proteins derived from a prostate cancer (LNCaP) cell line treated with delta-tocotrienol, (a form of Vitamin E). Users can obtain meaningful data through manipulation of the gel images being produced to find out what is happening at the molecular level.
This product line for disease case-control studies of DNA consists of 180 cases and 180 matched controls in ready-made 96- and 384-well plate formats with de-identified covariate data. Samples for diabetes, obesity, breast, colon, lung, and prostate cancer are available.